Adimab in Lebanon is offering its proprietary technology to aid in the development of antibody and multispecific therapeutic modalities. These technologies are the result of a collaboration between Adimab’s Computational Biology team in Palo Alto, CA, and its antibody engineering team in Lebanon, NH.
Adimab has released first-generation heavy chain-only antibody (HCAb) libraries to meet the growing demand for single-domain antibodies. Designed with the aid of novel machine learning methodology trained on extensive internal data from our commercially validated synthetic human IgG libraries as well as natural VHH repertoires, the HCAb libraries aim to minimize developability risk while ensuring high sequence diversity and broad epitope coverage. Utilizing the Adimab HCAb libraries follows the same efficient workflows and timelines of our standard IgG discovery and optimization process.
To support multispecific antibody programs, Adimab has employed both extensive structural modeling and directed protein evolution to derive novel heterodimerization solutions both at the heavy chain/light chain interface as well as the heavy chain interface in the CH3 domain. This readily allows for the formation of an IgG-like bispecific from any two antibodies, or the flexibility to generate other multispecific therapeutic molecules.
Adimab has developed constant region mutations for Fc-silencing. Disabling Fc effector functions can be critical in certain therapeutic approaches and thus constitutes an important addition to our overall portfolio of Fc technologies. Adimab's Fc-silencing mutations allow its partners to exclusively focus the therapeutic impact of their antibody on the variable domain target specificity while maintaining favorable developability properties expected of full-length antibodies.
Adimab has developed specific Fc engineering solutions and screening assays that enable the half-life extension of therapeutic antibodies and multispecific molecules in humans. Recent data generated in a Phase I clinical trial demonstrated an IgG half-life exceeding three months.
Adimab has filed multiple patent families to protect the proprietary nature of these technologies.
"We are excited to see our extensive investments in exploratory research translate into tangible solutions that our partners value. Antibody drug developers are increasingly demanding more from their lead candidates. Having a portfolio of solutions is an important element of ensuring our partners' technical successes and progression of their molecules into the clinic," says Eric Krauland, chief scientific officer of Adimab.
"Our partners have complex technical needs and are seeking a competitive edge as they design and develop their programs. Our research team invests significant time and effort to expand our capabilities; however, before the launch of any Adimab technology, there needs to be a demonstrated level of quality and validation that matches our reputation," says Guy Van Meter, chief business officer of Adimab.